Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer

Volumn 121, Issue 6, 2015, Pages 883-892

  Doebele, Robert C ^a   Spigel, David ^b   Tehfe, Mustapha ^c   Thomas, Sachdev ^d   Reck, Martin ^e   Verma, Sunil ^f   Eakle, Janice ^g   Bustin, Frederique ^h   Goldschmidt, Jerome ⁱ   Cao, Dachuang ^j   Alexandris, Ekaterine ^j   Yurasov, Sergey ^k   Camidge, D Ross ^a   Bonomi, Philip ^l  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Oncology and Hematology Associates of Central Illinois   (United States)

^e GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^g Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^h Neonatal Intensive Care Unit   (Belgium)

ⁱ Oncology and Hematology Associates of Southwest VA   (United States)

^j ELI LILLY AND COMPANY   (United States)

^k Clovis Oncology Inc   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Non small cell lung cancer (NSCLC); Nonsquamous; Pemetrexed; Platinum; Ramucirumab; Vascular endothelial growth factor (VEGF)

Indexed keywords

CARBOPLATIN; CISPLATIN; PEMETREXED; PLATINUM COMPLEX; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANAL HEMORRHAGE; ANEMIA; ANGINA PECTORIS; ANUS DISEASE; ARTERY THROMBOSIS; ARTICLE; BACKACHE; BLEEDING; BONE METASTASIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CARDIOPULMONARY INSUFFICIENCY; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; ELEVATED BLOOD PRESSURE; EMBOLISM; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEADACHE; HEALING IMPAIRMENT; HEART INFARCTION; HEMATOMA; HEMATOTHORAX; HEMATURIA; HEMOPTYSIS; HEMORRHOID HEMORRHAGE; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; INJECTION SITE BLEEDING; INSOMNIA; INTESTINE ISCHEMIA; INTRAOCULAR HEMORRHAGE; LARGE CELL CARCINOMA; LEG THROMBOSIS; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PETECHIA; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SQUAMOUS CELL LUNG CARCINOMA; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; VAGINA BLEEDING; VEIN THROMBOSIS; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; YOUNG ADULT;

EID: 84924207092     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29132     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
3. American Cancer Society. Lung cancer (non-small cell). http:// www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf. pdf. Accessed May, 29, 2014.
4. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218.
5. Scagliotti GV, De Marinis F, Rinaldi M, et al; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285-4291.
6. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
7. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-3024.
8. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
9. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253-263.
10. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895-2902.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
12. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21:505-515.
13. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
14. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996;7:259-270.
15. Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs. 1999; 17:195-212.
16. Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets. 2002;2:135-156.
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
18. Lu D, Shen J, Vil MD, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003;278:43496-43507.
19. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer. 2002;97:393-399.
20. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
21. Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-39.
22. Wilke H, Muro K, Van Cutsem E, et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15: 1224-1235.
23. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinumbased therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-673.
24. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219-1230.
25. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11:1172-1183.
26. Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol. 2012;13:e427-e436.